KR20040011469A - 히드록시프로필메틸셀룰로스 프탈레이트 중합체의 고체분산을 포함하는 약학 조성물 - Google Patents

히드록시프로필메틸셀룰로스 프탈레이트 중합체의 고체분산을 포함하는 약학 조성물 Download PDF

Info

Publication number
KR20040011469A
KR20040011469A KR10-2003-7011174A KR20037011174A KR20040011469A KR 20040011469 A KR20040011469 A KR 20040011469A KR 20037011174 A KR20037011174 A KR 20037011174A KR 20040011469 A KR20040011469 A KR 20040011469A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
polymer
solid dispersion
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-7011174A
Other languages
English (en)
Korean (ko)
Inventor
베이트먼니콜라
카힐줄리
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20040011469A publication Critical patent/KR20040011469A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2003-7011174A 2001-02-27 2002-02-25 히드록시프로필메틸셀룰로스 프탈레이트 중합체의 고체분산을 포함하는 약학 조성물 Withdrawn KR20040011469A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
GB0104752.1 2001-02-27
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (1)

Publication Number Publication Date
KR20040011469A true KR20040011469A (ko) 2004-02-05

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7011174A Withdrawn KR20040011469A (ko) 2001-02-27 2002-02-25 히드록시프로필메틸셀룰로스 프탈레이트 중합체의 고체분산을 포함하는 약학 조성물

Country Status (14)

Country Link
US (1) US20040138231A1 (https=)
EP (1) EP1365746A1 (https=)
JP (1) JP2004527489A (https=)
KR (1) KR20040011469A (https=)
CN (1) CN1533268A (https=)
BR (1) BR0206960A (https=)
CA (1) CA2435815A1 (https=)
GB (1) GB0104752D0 (https=)
IL (1) IL156830A0 (https=)
MX (1) MXPA03006746A (https=)
NO (1) NO20033782D0 (https=)
NZ (1) NZ527080A (https=)
WO (1) WO2002067904A1 (https=)
ZA (1) ZA200305386B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびhpmcasを含む固体分散物中の経口用薬学的組成物
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (https=) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
WO1995005809A1 (en) * 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
PT1082321E (pt) * 1998-05-02 2005-03-31 Astrazeneca Ab Derivados heterociclicos que inibem o factor xa
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs

Also Published As

Publication number Publication date
CN1533268A (zh) 2004-09-29
US20040138231A1 (en) 2004-07-15
MXPA03006746A (es) 2003-10-24
EP1365746A1 (en) 2003-12-03
NZ527080A (en) 2005-02-25
BR0206960A (pt) 2004-03-09
ZA200305386B (en) 2004-10-11
NO20033782L (no) 2003-08-26
JP2004527489A (ja) 2004-09-09
WO2002067904A1 (en) 2002-09-06
GB0104752D0 (en) 2001-04-18
NO20033782D0 (no) 2003-08-26
CA2435815A1 (en) 2002-09-06
IL156830A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
JP5775071B2 (ja) アピキサバンの製剤形
CA2793525C (en) Method for improving dissolution of anticoagulant agent
EP1297836A1 (en) COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED
US20110045028A1 (en) Sustained release preparation
CA2720851A1 (en) Oral pharmaceutical compositions in a molecular solid dispersion
CN105232488B (zh) 一种含有利伐沙班的固体药物组合物
EP2068835A2 (en) Imatinib compositions
SG176934A1 (en) Pharmaceutical composition having improved solubility
KR20040011469A (ko) 히드록시프로필메틸셀룰로스 프탈레이트 중합체의 고체분산을 포함하는 약학 조성물
KR20180069068A (ko) 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
AU2002233882A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
WO2025133629A1 (en) Tablet formulations involving alvelestat
WO2024200335A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
KR20220040169A (ko) 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제
US20090061000A1 (en) Pharmaceutical formulation use 030
HK1164738B (en) Dosage forms of apixaban
HK1164738A (en) Dosage forms of apixaban
HK40012633A (en) Dosage forms of apixaban
HK1168790A (en) Pharmaceutical composition having improved solubility
HK1180252B (en) Method for improving dissolvability of anticoagulant

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid